Sheldon L Kaplan1, Kimberly J Center2, William J Barson3, Philana Ling-Lin4, José R Romero5, John S Bradley6, Tina Q Tan7, Jill A Hoffman8, Timothy R Peters9, Alejandra Gurtman2, Daniel A Scott2, James Trammel10, William C Gruber2, Kristina G Hulten1, Edward O Mason1. 1. Pediatric Infectious Diseases Sections, Baylor College of Medicine, Houston, Texas. 2. Pfizer Vaccine Research, Collegeville, Pennsylvania Pfizer Vaccine Research, Pearl River, New York. 3. The Ohio State University College of Medicine and Public Health, Columbus. 4. Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center, Pennsylvania. 5. University of Arkansas for Medical Sciences, Little Rock. 6. Rady Children's Hospital San Diego, California. 7. Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 8. University of Southern California School of Medicine, Los Angeles. 9. Wake Forest School of Medicine, Winston-Salem, North Carolina. 10. inVentive Health Clinical, Princeton, New Jersey.
Abstract
BACKGROUND: Streptococcus pneumoniae is a common cause of otitis media (OM) in children; mastoiditis remains an important complication of OM. Limited data are available on the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal otitis. METHODS: Investigators from 8 children's hospitals in the United States prospectively collected pneumococcal isolates from middle ear or mastoid cultures from children from 2011 to 2013. Serotype and antibiotic susceptibilities were determined and PCV13 doses for children documented. RESULTS: Over the 3-year period, the proportion of isolates included in PCV13 (plus a related serotype) decreased significantly (P = .0006) among the middle ear/mastoid isolates (2011, 50% [74/149]; 2012, 40.5% [47/116]; 2013, 29% [34/118]). The number of serotype 19A isolates in 2013 (n = 12, 10.2% of total) decreased 76% compared with the number of 19A isolates in 2011 (n = 50, 33.6% of total). Of the children from whom serotype 19A was isolated (n = 93), 55% had previously received <3 doses of PCV13. The most common non-PCV13 serotypes for the combined years were 35B (n = 37), 21 (n = 20), 23B (n = 20), 15B (n = 18), 11 (n = 17), 23A (n = 14), 15A (n = 14), and 15C (n = 14). The proportion of isolates with a penicillin minimal inhibitory concentration >2 µg/mL decreased significantly over the 3 years (2011, 22% [35/154]; 2012, 20% [24/118]; 2013, 10% [12/120]; P < .02). CONCLUSIONS: The number of pneumococcal isolates and the percentage of isolates with high-level penicillin resistance from cultures taken from children with OM or mastoiditis for clinical indications have decreased following PCV13 use, largely related to decreases in serotype 19A isolates.
BACKGROUND:Streptococcus pneumoniae is a common cause of otitis media (OM) in children; mastoiditis remains an important complication of OM. Limited data are available on the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal otitis. METHODS: Investigators from 8 children's hospitals in the United States prospectively collected pneumococcal isolates from middle ear or mastoid cultures from children from 2011 to 2013. Serotype and antibiotic susceptibilities were determined and PCV13 doses for children documented. RESULTS: Over the 3-year period, the proportion of isolates included in PCV13 (plus a related serotype) decreased significantly (P = .0006) among the middle ear/mastoid isolates (2011, 50% [74/149]; 2012, 40.5% [47/116]; 2013, 29% [34/118]). The number of serotype 19A isolates in 2013 (n = 12, 10.2% of total) decreased 76% compared with the number of 19A isolates in 2011 (n = 50, 33.6% of total). Of the children from whom serotype 19A was isolated (n = 93), 55% had previously received <3 doses of PCV13. The most common non-PCV13 serotypes for the combined years were 35B (n = 37), 21 (n = 20), 23B (n = 20), 15B (n = 18), 11 (n = 17), 23A (n = 14), 15A (n = 14), and 15C (n = 14). The proportion of isolates with a penicillin minimal inhibitory concentration >2 µg/mL decreased significantly over the 3 years (2011, 22% [35/154]; 2012, 20% [24/118]; 2013, 10% [12/120]; P < .02). CONCLUSIONS: The number of pneumococcal isolates and the percentage of isolates with high-level penicillin resistance from cultures taken from children with OM or mastoiditis for clinical indications have decreased following PCV13 use, largely related to decreases in serotype 19A isolates.
Authors: Yi Li; Andrew Hill; Marie Beitelshees; Shuai Shao; Jonathan F Lovell; Bruce A Davidson; Paul R Knight; Anders P Hakansson; Blaine A Pfeifer; Charles H Jones Journal: Proc Natl Acad Sci U S A Date: 2016-06-06 Impact factor: 11.205
Authors: Liset Olarte; Sheldon L Kaplan; William J Barson; José R Romero; Philana Ling Lin; Tina Q Tan; Jill A Hoffman; John S Bradley; Laurence B Givner; Edward O Mason; Kristina G Hultén Journal: J Clin Microbiol Date: 2016-11-09 Impact factor: 5.948
Authors: Melinda M Pettigrew; Mark R Alderson; Lauren O Bakaletz; Stephen J Barenkamp; Anders P Hakansson; Kevin M Mason; Johanna Nokso-Koivisto; Janak Patel; Stephen I Pelton; Timothy F Murphy Journal: Otolaryngol Head Neck Surg Date: 2017-04 Impact factor: 3.497